The purpose of this trial is to test the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with metastatic uveal melanoma.
Eligible patients include those with metastatic uveal melanoma who are ≥ 18 years of age, and are physically able to tolerate non-myeloablative chemotherapy and high-dose aldesleukin.
Patients will undergo surgical biopsy or resection of a metastatic tumor on the companion protocol HCC 17-220 (Cell Harvest and Preparation to Support Adoptive Cell Therapy Clinical Protocols and Pre-Clinical Studies). There is no requirement for prior systemic therapies, given the lack of known effective systemic treatments for metastatic uveal melanoma.
Initiated by the UPMC Immune Transplant and Therapy Center.